1. 617PDA phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data. (23rd October 2018) Authors: Satoh, T; Chen, L-T; Kang, Y-K; Chao, Y; Kato, K; Chung, H C; Chen, J-S; Muro, K; Kang, W K; Yoshikawa, T; Oh, S C; Tamura, T; Lee, K-W; Boku, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 680PA phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01). (23rd October 2018) Authors: Lee, K-W; Maeng, C H; Kim, T-Y; Zang, D Y; Kim, Y H; Hwang, I G; Oh, S C; Chung, J S; Song, H S; Kim, J W; Jeong, S J; Cho, J Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗